| Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer RL Steinberg, LJ Thomas, N Brooks, SL Mott, A Vitale, T Crump, MY Rao, ... The Journal of Urology 203 (5), 902-909, 2020 | 129 | 2020 |
| Microfluidic Tumor–Vascular Model to Study Breast Cancer Cell Invasion and Intravasation S Nagaraju, D Truong, G Mouneimne, M Nikkhah Advanced healthcare materials 7 (9), 1701257, 2018 | 129 | 2018 |
| Poly (N-isopropylacrylamide)-based dual-crosslinking biohybrid injectable hydrogels for vascularization A Pal, CI Smith, J Palade, S Nagaraju, BA Alarcon-Benedetto, J Kilbourne, ... Acta biomaterialia 107, 138-151, 2020 | 25 | 2020 |
| The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non‐muscle‐invasive bladder cancer treated with bacillus Calmette–Guérin NA Brooks, A Kokorovic, L Xiao, JT Matulay, R Li, WKB Ranasinghe, ... BJU international 128 (1), 65-71, 2021 | 12 | 2021 |
| Bacillus Calmette-Guerin retains clinically relevant viability for up to 72 hours after reconstitution: potential implications for clinical practice in times of shortage N Brooks, S Nagaraju, J Matulay, XY Han, AM Kamat European Urology Oncology 4 (5), 826-828, 2021 | 6 | 2021 |
| Enhancing oral delivery of plant-derived vesicles for colitis. Y Liu, AL Ahumada, E Bayraktar, P Schwartz, M Chowdhury, S Shi, ... Journal of Controlled Release: Official Journal of the Controlled Release …, 2023 | 3 | 2023 |
| Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes PJ Hensley, KK Bree, N Brooks, J Matulay, R Li, GM Nogueras-Gonzalez, ... European Urology Oncology, 2021 | 2 | 2021 |
| A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guérin in patients with non-muscle invasive bladder carcinoma: A … GM Villoldo, MT Pombo, M Aris, J Chemi, P Mandó, S Nagaraju, ... Oncology Research 31 (2), 207, 2023 | 1 | 2023 |
| BCG shortage: Reassessing the clinical viability of Bacillus Calmette-Guerin (BCG) after reconstitution. N Brooks, S Nagaraju, JT Matulay, XY Han, AM Kamat Journal of Clinical Oncology 38 (6_suppl), 534-534, 2020 | 1 | 2020 |
| MP43-04 CONTEMPORARY OUTCOMES OF NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH INDUCTION BCG J Matulay*, R Li, N Navai, S Nagaraju, V Narayan, A Lim, HB Grossman, ... The Journal of Urology 201 (Supplement 4), e618-e618, 2019 | 1 | 2019 |
| Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy S Corvigno, Y Liu, E Bayraktar, E Stur, NN Bayram, AL Ahumada, ... npj Precision Oncology 8 (1), 86, 2024 | | 2024 |
| Enhancing oral delivery of plant-derived vesicles Y Liu, A Lankenau-Ahumada, E Bayraktar, P Schwartz, M Chowdhury, ... Cancer Research 83 (7_Supplement), 2720-2720, 2023 | | 2023 |
| Multi-Institution Evaluation of Sequential Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin Naïve Patients with Non-Muscle Invasive Bladder … LJ Thomas, RL Steinberg, VT Packiam, IM McElree, N Brooks, A Vitale, ... Clinical Genitourinary Cancer, 2022 | | 2022 |
| A Th2-score in the tumor microenvironment as a predictive biomarker of response to BCG in patients with non-muscle invasive bladder carcinoma. A retrospective study. GM Villoldo, MT Pombo, M Aris, J Chemi, P Mandó, S Nagaraju, ... | | 2022 |
| Implications of guideline-based, risk-stratified restaging transurethral resection of HG Ta urothelial carcinoma on BCG therapy outcomes P Hensley, K Bree, N Brooks, J Matulay, R Li, G Nogueras-Gonzalez, ... JOURNAL OF UROLOGY 206, E123-E123, 2021 | | 2021 |
| PD63-04 ALL HIGH-GRADE NMIBC IS HIGH RISK: BCG RESPONSE IN HIGH-GRADE TA TUMORS K Bree, N Brooks, G Nogueras-Gonzalez, S Nagaraju, HB Grossman, ... The Journal of Urology 206 (Supplement 3), e1139-e1139, 2021 | | 2021 |
| MP48-14 UTUC SURVEILLANCE FOLLOWING BCG-TREATED NMIBC: TIMING AND RISK FACTORS ASSOCIATED WITH RECURRENCE K Bree, P Hensley, N Brooks, S Nagaraju, N Navai, C Dinney, S Matin, ... The Journal of Urology 206 (Supplement 3), e870-e870, 2021 | | 2021 |
| PD09-09 IMPLICATIONS OF GUIDELINE-BASED, RISK-STRATIFIED RESTAGING TRANSURETHRAL RESECTION OF HG TA UROTHELIAL CARCINOMA ON BCG THERAPY OUTCOMES P Hensley, K Bree, N Brooks, J Matulay, R Li, G Nogueras-Gonzalez, ... The Journal of Urology 206 (Supplement 3), e123-e123, 2021 | | 2021 |
| Light-activated molecular nanomachines kill bladder cancer cells S Nagaraju, A van Venrooy, PJ Hensley, KK Bree, C Ayala-Orozco, ... Cancer Research 81 (13 Supplement), 267-267, 2021 | | 2021 |
| Restaging Transurethral Resection of HG Ta Bladder Tumors: A Risk-Adapted Approach PJ Hensley, K Bree, N Brooks, J Matulay, S Nagaraju, N Navai, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 900-901, 2020 | | 2020 |
Ashish M. Kamat, MD, MBBS, FACSProfessor, MD Anderson Cancer CenterVerifierad e-postadress på mdanderson.org
